Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CDX-585 |
| Trade Name | |
| Synonyms | CDX 585|CDX585 |
| Drug Descriptions |
CDX-585 is a bispecific antibody that targets PD-1 and LILRB2 (ILT4), potentially resulting in enhanced antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 2963). |
| DrugClasses | LILRB2 Antibody 12 PD-L1/PD-1 antibody 136 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CDX-585 | CDX-585 | 0 | 1 |